



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PATH Essential Medicines, PATH, Seattle, WA, USA (DCK); Global Healthcare Consulting, New Delhi, India (SK); Department of Global Health, University of Washington, Seattle, WA, USA (SK); STAR Program, Public Health Institute, Washington DC, USA (FO); Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico (AC); Department of Health Security at the Finnish Institute for Health and Welfare, Helsinki, Finland (HN)

- 1 Shrotri M, Swinnen T, Kampmann B, Parker EPK. An interactive website tracking COVID-19 vaccine development. *Lancet Glob Health* 2021; **9**: e590–92.
- 2 WHO. COVID-19 vaccines technical documents. <https://www.who.int/groups/strategic-advisory-group-of-experts-on-immunization/covid-19-materials> (accessed Jan 10, 2022).
- 3 Skowronski DM, Setayeshgar S, Febriani Y, et al. Two-dose SARS-CoV-2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. *medRxiv* 2021; published online Oct 26. <https://doi.org/10.1101/2021.10.26.21265397> (preprint).
- 4 Araos R, Jara A. COVID-19 vaccine effectiveness assessment in Chile. Oct 25, 2021. https://cdn.who.int/media/docs/default-source/blue-print/chile_rafael-araos_who-vr-call_25oct2021.pdf?sfvrsn=7a7ca72a_7 (accessed Nov 29, 2021).
- 5 Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, et al. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. *Euro Surveill* 2021; **26**:2100894.
- 6 Andrews N, Stowe J, Kirsebom F, Gower C, Ramsay M, Bernal JL. Effectiveness of BNT162b2 (Comirnaty, Pfizer-BioNTech) COVID-19 booster vaccine against COVID-19 related symptoms in England: test negative case-control study. *medRxiv* 2021; published online Nov 15, 2021. <https://doi.org/10.1101/2021.11.15.21266341>.
- 7 Tan CS, Collier A-r, Liu J, et al. Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant. *medRxiv* 2021; published online Dec 30. <https://doi.org/10.1101/2021.12.02.21267198>.
- 8 Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. *Nature* 2021; **600**: 701–06.
- 9 Liu X, Shaw RH, Stuart ASV, et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. *Lancet* 2021; **398**: 856–69.
- 10 Shaw RH, Stuart A, Greenland M, Liu X, Nguyen Van-Tam JS, Snape MD. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. *Lancet* 2021; **397**: 2043–46.
- 11 Normark J, Vikström L, Gwon YD, et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 vaccination. *N Engl J Med* 2021; **385**: 1049–51.
- 12 Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. *Lancet Respir Med* 2021; **9**: 1255–65.
- 13 Buchan SA, Seo CY, Johnson C, et al. Epidemiology of myocarditis and pericarditis following mRNA vaccines in Ontario, Canada: by vaccine product, schedule and interval. *medRxiv* 2021; published online Dec 5. <https://doi.org/10.1101/2021.12.02.21267156>.



COVID-19 vaccine results might inform malaria vaccine strategies

Published Online
February 24 2022
[https://doi.org/10.1016/S1473-3099\(22\)00139-6](https://doi.org/10.1016/S1473-3099(22)00139-6)

Interim Com-COV2 trial data evaluated two-dose COVID-19 vaccination regimens with first dose of BNT162b2 (Pfizer-BioNTech) or ChAdOx1 nCoV-19 (Oxford-AstraZeneca) alongside second dose as either homologous vaccination, heterologous NVX-CoV2373 (Novavax) vaccination, or heterologous mRNA-1273 (Moderna) vaccination.¹ These data showed that ChAdOx1 nCoV-19 vaccination followed by NVX-CoV2373 vaccination drove optimal T-cell immunogenicity and excellent antibody induction. These heterologous vaccine approach findings are now likely to be extrapolated in developing scheduling strategies for other vaccines. We are particularly interested in the potential impact of these findings on malaria vaccine strategies. Could heterologous approaches with protein-in-adjuvant boosters improve future malaria vaccine efficacy?

Malaria vaccine development is hindered by the complex life cycle and immune evasive strategies of *Plasmodium falciparum*. Like COVID-19, repeated infections with malaria are possible, presenting a challenge to the design of vaccines that can provide

lifelong protection. These issues have created barriers to the goal of the so-called holy grail in malaria vaccination, a candidate that targets all key stages of the *P falciparum* life cycle, including vector stages, to reduce transmission. The WHO recommendation on Oct 6, 2021, of the use of a malaria vaccine in the form of RTS,S/AS01 (RTS,S) shows how far we have come. RTS,S stimulates immunogenicity through induction of antibodies to the NANP region of the circumsporozoite protein. This antigen is fused to the hepatitis B surface antigen alongside an adjuvant of AS01. With a global aim to license a vaccine with 75% efficacy by 2030, RTS,S is unlikely to be sufficient alone. Another pre-erythrocytic protein-in-adjuvant malaria vaccine, which also incorporates hepatitis B surface antigen and circumsporozoite protein, is R21. R21 has recently shown efficacy exceeding WHO targets in phase 2b trials in Burkina Faso.² This vaccine uses the adjuvant Matrix-M, similar to the NVX-CoV2373 COVID-19 vaccine that also uses a recombinant protein with Matrix-M. The Com-COV2 results suggest that perhaps a future malaria vaccine regimen might incorporate, for example, RTS,S

as a first dose and an R21 booster. This booster of protein (circumsporozoite protein) in adjuvant (Matrix-M) might optimise immunogenicity responses against circumsporozoite protein.

Heterologous viral vector approaches have long aimed to optimise T-cell responses. Ongoing research interest in adenoviral vectors showed ChAd63-modified vaccinia virus Ankara with ME-TRAP antigen induced polyfunctional T-cell activity of high magnitude.³ T-cell immunity is a significant correlate of protection for malaria, and insufficient cellular immunogenicity might limit efficacy and durability of vaccine candidates. In murine models, adoptive transfer of MHC-activated CD8+ T cells targeting Plasmodium selectively reduced hepatocyte parasitic burden.⁴ For the RTS,S vaccine, several epitopes have been matched to CD4+ cell responses.⁵ Indeed, the magnitude of T-cell ELISPOT responses after viral vector-based immunisation strategies has been correlated with malaria protection and presence of memory cell population at 6 months post-sporozoite challenge.⁶ Heterologous adenoviral vaccination regimens have been widely used with the rollout of the Sputnik V COVID-19 vaccine, using adenovirus 26 and adenovirus 5 vectors.⁷ Our understanding of adenoviral vaccines has markedly improved through their licensing during the COVID-19 pandemic. The combination of a viral vector and protein-in-adjuvant has been trialled in malaria, including a range of antigens in addition to differing platforms. The combination of RTS,S (based on circumsporozoite protein) and viral vectors that express an optimised antigen known as ME-TRAP produced high sterile efficacy against parasitic challenge.⁸ By using a range of antigens in this approach, heterologous malaria vaccine strategies could incorporate blood-stage antigenic targets to enhance breadth of immunogenicity—eg, using blood-stage antigen RH5 in combination with existing targets, such as circumsporozoite protein.

We have learned from COVID-19 vaccination strategies that a greater interval between first and second dose can enhance immunogenicity, as seen in those who received ChAdOx1 nCoV-19.⁹ A phase 3 trial showed delayed administration of even fractional third doses in an RTS,S course can enhance immunogenicity,¹⁰ and so consideration of delayed booster doses alongside heterologous strategies could optimise vaccine strategy.

The Com-COV2 findings provide new insights into enhancing vaccine immunogenicity and suggest

that heterologous combination vaccine approaches incorporating Matrix-M boosting could be translated for use in malaria vaccinology to optimise cellular immune responses. Mixed vaccine approaches incorporating recombinant protein, adenoviral, and bloodstream vaccine candidates could pave the way towards the holy grail of malaria vaccine strategy.

Guy's and St Thomas' Foundation Trust has received a grant from Novavax. ALG has been involved in non-commercial leadership of a malaria vaccine trial incorporating Matrix-M (VAC072)—this trial was sponsored by the University of Oxford. ALG has previously worked at the University of Oxford, which holds the patent on the promotor construct that is often used in ChAdOx1-vectored vaccines. ALG holds no correct affiliation with the University of Oxford, but is named on this patent held in the name of the university. Funds were given to charity in lieu of honoraria for ALG speaking on vaccines. Oxford University has entered a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. ALG is named as an inventor on a patent covering use of a particular promoter construct that is often used in ChAdOx1-vectored vaccines and is incorporated in the ChAdOx1 nCoV-19 vaccine. ALG might benefit from royalty income paid to the University of Oxford from sales of this vaccine by AstraZeneca and its sublicensees under the University's revenue sharing policy.

**Movin Abeywickrema, Anna L Goodman*

movin.abeywickrema@gstt.nhs.uk

Clinical Research Facility (MA) and Department of Infection (ALG), St Thomas' Hospital, Guy's and St Thomas' Foundation Trust, London SE1 7EH, UK; MRC Clinical Trials Unit, University College London, London, UK (ALG)

- 1 Stuart ASV, Shaw RH, Liu X, et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *Lancet* 2022; **399**: 36–49.
- 2 Dattoo MS, Natama MH, Somé A, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. *Lancet* 2021; **397**: 1809–18.
- 3 Ewer KJ, O'Hara GA, Duncan CJA, et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. *Nat Commun* 2013; **4**: 2836.
- 4 Huang J, Tsao T, Zhang M, Rai U, Tsuji M, Li X. A sufficient role of MHC class I molecules on hepatocytes in anti-plasmodial activity of CD8 (+) T cells in vivo. *Front Microbiol* 2015; **6**: 69.
- 5 Kazmin D, Nakaya HI, Lee EK, et al. Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. *Proc Natl Acad Sci USA* 2017; **114**: 2425–30.
- 6 Keating SM, Bejon P, Berthoud T, et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. *J Immunol* 2005; **175**: 5675–80.
- 7 Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* 2021; **397**: 671–81.
- 8 Rampling T, Ewer KJ, Bowyer G, et al. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. *NPJ Vaccines* 2018; **3**: 49.
- 9 Flaxman A, Marchevsky NG, Jenkin D, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet* 2021; **398**: 981–90.
- 10 Regules JA, Cicatelli SB, Bennett JW, et al. Fractional third and fourth dose of RTS,S/AS01 malaria candidate vaccine: a phase 2a controlled human malaria parasite infection and immunogenicity study. *J Infect Dis* 2016; **214**: 762–71.